FY2024 EPS Estimates for MediWound Reduced by HC Wainwright

MediWound Ltd. (NASDAQ:MDWD) – Analysts at HC Wainwright reduced their FY2024 earnings estimates for shares of MediWound in a note issued to investors on Wednesday, November 27th. HC Wainwright analyst S. Ramakanth now expects that the biopharmaceutical company will earn ($2.61) per share for the year, down from their previous estimate of ($2.14). HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for MediWound’s current full-year earnings is ($2.47) per share. HC Wainwright also issued estimates for MediWound’s Q4 2024 earnings at ($0.54) EPS, Q1 2025 earnings at ($0.56) EPS, Q2 2025 earnings at ($0.64) EPS, Q3 2025 earnings at ($0.71) EPS, Q4 2025 earnings at ($0.77) EPS, FY2025 earnings at ($2.69) EPS, FY2026 earnings at ($1.87) EPS, FY2027 earnings at ($0.80) EPS and FY2028 earnings at $1.06 EPS.

Separately, StockNews.com upgraded MediWound to a “sell” rating in a research report on Monday, August 5th.

MediWound Price Performance

Shares of MDWD stock opened at $18.10 on Monday. MediWound has a 12-month low of $8.81 and a 12-month high of $24.00. The firm has a market capitalization of $195.25 million, a price-to-earnings ratio of -6.24 and a beta of 0.83. The business has a 50 day simple moving average of $17.17 and a 200 day simple moving average of $17.38.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in MDWD. MetLife Investment Management LLC bought a new stake in MediWound during the third quarter worth approximately $89,000. Rhumbline Advisers acquired a new position in shares of MediWound during the 2nd quarter valued at $131,000. Barclays PLC lifted its holdings in shares of MediWound by 311.3% in the third quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company’s stock valued at $202,000 after buying an additional 8,449 shares during the period. Point72 Asset Management L.P. acquired a new stake in shares of MediWound in the third quarter valued at $212,000. Finally, Bank of New York Mellon Corp acquired a new position in MediWound during the second quarter worth about $342,000. 46.83% of the stock is currently owned by institutional investors.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.